Matías Sánchez retweeted
Felicitaciones @erivaserra por un #ISA perfecto. @ISA_Amyloidosis
LATAM está para grandes cosas!!!!
Por más proyectos colaborativos en la región :)
@gelamm_latam – at Montevideo, Uruguay
Matías Sánchez retweeted
So many great abstracts to be presented at ASH 2026. Here’s my top 10 in myeloma, with a focus on drugs with impending regulatory potential, novel agents/regimens, and updated data that’s relevant!
Let’s go!....
Yi Lin, MD, PhD, describes the science behind a phase 1 study of anitocabtagene autoleucel, a CAR T cell that deploys a CAR with a novel synthetic antigen-binding domain, in patients with multiple myeloma.
Learn more about the science behind the study in the editorial “Anito-cel for Multiple Myeloma”: nej.md/4hF5Gxj
Matías Sánchez retweeted
Yesterday was a glorious day of science @nyugrossman @nyulangone with two fantastic papers
1st by @giladevrony on impact of caloric restriction on mutation rates:
cell.com/cell/fulltext/S0092…
2nd by @MarcusDGon @eze_dantas on refined starches & immune markers
cell.com/cell-press-blue/ful…
Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker–DeBakey Clinical Medical Research Award.
Read more about their work in the Clinical Implications of Basic Research article “Reengineering Coagulation with a Bispecific Antibody” by Flora Peyvandi, MD, PhD: nej.md/4cFbvZ5

ALT This illustrated diagram from the Clinical Implications of Basic Research article "Reengineering Coagulation with a Bispecific Antibody" shows the engineering of emicizumab. Panels A, B, and C summarize the key features of the nonclinical discovery research and clinical use of emicizumab, a humanized bispecific monoclonal antibody. Panel D illustrates the mechanism of action of emicizumab, which simultaneously binds activated factor IX (factor IXa) and factor X, functionally replacing the cofactor activity of factor VIIIa.
Matías Sánchez retweeted
En este día, saludamos a todos nuestros pacientes y a sus familias y cuidadores.
Seguiremos trabajando por la visibilidad del #mieloma
Nos debemos a uds!!
@gelamm_latam #mmsm – at Llanquihue, Chile
Matías Sánchez retweeted
🧵 Myeloma community: CMS is considering an important change to Medicare coverage for autologous stem cell transplant (ASCT). Comments are needed.
CMS proposal + comment submission:
cms.gov/medicare-coverage-da…
@RahulBanerjeeMD @AlGarfall @End_myeloma @SurbhiSidanaMD @DrKrinaPatel
Matías Sánchez retweeted
Excited to see our How I Treat Article on Infection Prevention in Patients receiving Bispecific Antibodies out today in full print in @BloodPortfolio !
Great working on this piece with @RahulBanerjeeMD and @JoshuaHillMD 💪
@LMU_Muenchen @fredhutch
ashpublications.org/blood/ar…
Matías Sánchez retweeted
🚨🚨🚨 Help preserve transplants for 🇺🇸 pts with myeloma!
All patients, MDs, RNs, & anyone who knows transplant is good option for Medicare beneficiaries:
Please comment on CMS proposed memo by Aug 29th. Link 👇🏼
This is a big deal. ASCT no longer covered for ISS stage I 🤯
Matías Sánchez retweeted
For physicians who deal with lots of referrals on “abnormal free light chain ratio” incidental finding.
Our recommendation is unless the FLC ratio is <0.125 or >8 or unless you are worried about myeloma clinically, or dealing with biopsy proven AL amyloid or MIDD or PGNMID, ask referring physicians to repeat in 6 months and if stable consider it as possible LC-MGUS with subsequent testing only if symptoms concerning for myeloma, amyloid etc develop. Defer bone marrow biopsy or bone survey.
See algorithm below. @nejm
Note labs report K/L ratio. Not involved /uninvolved. For ease of use you can calculate involved (high value) / uninvolved (low value). And use 8 as cut off as shown in figure. Otherwise you have to follow one cutoff for lambda and one for kappa.
nejm.org/doi/abs/10.1056/NEJ…
Matías Sánchez retweeted
1/3 Our manuscript evaluating association of CAR-T kinetics and toxicity in myeloma @HitomiHosoyaMD
✅Cilta-cel expansion >>> ide-cel
✅Rapid peak cilta-cel expansion correlates with delayed NT
✅ALC good surrogate of CAR expansion in 1st 4 weeks
ashpublications.org/blood/ar…
Excited to share our collaboration with @FrancescaCottin @pierrerod @Anitaavilar @KarenSweiss @DamianoRondell1 on the benefit of maintenance therapy after induction in plasma cell MGRS. Longer treatment is better ashpublications.org/bloodadv…
Matías Sánchez retweeted
Congratulations to the ENDURANCE investigators on an impactful trial - they should be applauded for running a successful cooperative group phase 3 trial with two randomizations! My thoughts below...
ENDURANCE enrolled patients without high-risk disease and without intention for ASCT.
The 1st randomization evaluated KRd vs. VRd (no difference in PFS).
The 2nd randomization evaluated 2 years vs indefinite lenalidomide maintenance with OS as the primary endpoint. After 9 years of follow-up, there is no difference in OS!
Let's dive in and take a closer look...
nejm.org/doi/full/10.1056/NE…
Matías Sánchez retweeted
How long from protocol to paper? This one is 15 years.
RCTs especially IITs are hard work. @myelomaMD pulled it off through unbelievable hard work.
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI
Implications are HUGE. This is a drug we spends billions on each year:
-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD
National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG
nejm.org/doi/full/10.1056/NE…
And @AmericanAir did it again! , flight AA 912 from SCL to MIA , aborted after 1 hour flying due to a maintenance issues . Trying to fly for the last 2 days…🙄#americanair #unreliable #dontflyaa #delayed #worstairline #getyouracttogether
Another delayed flight on @AmericanAir AA2910 ORD to MIA , apparently “uncontrollable cabin temperature” While we value our security, it would be nice if you could keep passengers updated and facilitate rebooking. Will avoid flying with you in the future
Today 7/4 on @AmericanAir My Flight AA912 from SCL to MIA was returned to SCL , one hour after departure , due to a failed temperature reader . I thank the pilot for a bringing us back safely. Forget about missing connecting flight .Now I am more worried @AmericanAir safety
Matías Sánchez retweeted
Practical guide to using Bela. Thank you @RobertoMinaMD for leading this effort which I hope will be a useful guide for both academic and community docs with @PlasmaCellPete @bhemato @szusmani @mvmateos @JoshuaRichterMD @DrRakeshPopat @AjayNookaMD @SagarLonialMD
Matías Sánchez retweeted
Another delayed flight on @AmericanAir AA2910 ORD to MIA , apparently “uncontrollable cabin temperature” While we value our security, it would be nice if you could keep passengers updated and facilitate rebooking. Will avoid flying with you in the future
Matías Sánchez retweeted
Although all 4 trials were done in relapsed myeloma with 1-3 prior regimens, the type of patients varied including by type of prior exposure. So comparing head to head HRs is not advisable.
Patient and disease factors, access, affordability, and shared decision making come into play, especially in first relapse. In second relapse we have to also add belantamab. teapawt.org/openmedicinehq/status/…
Treatment of Myeloma: First Relapse algorithm from @VincentRK: myopenmedicine.com/algorithm…


























